Improving treatments for advanced prostate cancer
Enhancing the efficacy of androgen signaling inhibitors in prostate cancer
This project looks for new ways to make current prostate cancer medicines work better for patients whose cancer has become resistant to treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Kentucky NIH-funded |
| Lab location | 1 site (Lexington, United States) |
| Project ID | NIH-11123375 on NIH RePORTER |
What this research studies
Current prostate cancer drugs, like abiraterone and enzalutamide, help patients with advanced cancer but often stop working after a few months. This happens because the cancer cells find new ways to grow, even with treatment. Our goal is to understand why these drugs stop working and find new targets to make them more effective. We are exploring specific cell pathways, called Wnt signaling, that might be helping cancer cells resist treatment. By understanding and targeting these pathways, we hope to develop better strategies for patients with advanced prostate cancer.
Who could benefit from this research
Good fit: This research is relevant for patients with castration-resistant prostate cancer who are currently receiving or have previously received androgen signaling inhibitors.
Not a fit: Patients with early-stage prostate cancer or those not treated with androgen signaling inhibitors may not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could lead to new treatments that help current prostate cancer medicines work longer and more effectively for patients.
How similar studies have performed: While current androgen signaling inhibitors provide some benefit, this research explores novel pathways to overcome resistance, an area where existing approaches have limited long-term success.
Where this research is happening
Lexington, United States
- University of Kentucky — Lexington, United States (Active)
Researchers
- Principal investigator: Liu, Xiaoqi — University of Kentucky
- Study coordinator: Liu, Xiaoqi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.